The estimated Net Worth of Caroline Young is at least $26.4 Mille dollars as of 1 December 2022. Ms. Young owns over 379 units of Cumberland Pharmaceuticals stock worth over $26,444 and over the last 8 years she sold CPIX stock worth over $0. In addition, she makes $0 as Independent Director at Cumberland Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Young CPIX stock SEC Form 4 insiders trading
Caroline has made over 18 trades of the Cumberland Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 379 units of CPIX stock worth $849 on 1 December 2022.
The largest trade she's ever made was buying 1,714 units of Cumberland Pharmaceuticals stock on 11 July 2019 worth over $9,530. On average, Caroline trades about 284 units every 38 days since 2017. As of 1 December 2022 she still owns at least 19,587 units of Cumberland Pharmaceuticals stock.
You can see the complete history of Ms. Young stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Caroline Young biography
Caroline R. Young serves as Independent Director of the Company. Ms. Young was previously the President of the Nashville Health Care Council, a position she held from 2008 to 2015. Under her leadership, the Council’s membership grew to encompass 300 diverse organizations and launched the one-of-a-kind Fellows initiative designed to further the skills of business executives. Additionally, the Council’s innovative Leadership Health Care program expanded to consist of 1,000 members. Ms. Young joined the Council in 2004, serving as vice president. Prior to the Council, Ms. Young was the founding Executive Director of Life Science Tennessee from 2002 to 2004. She also served in communications roles for the State of Tennessee’s Department of Economic and Community Development (ECD) from 1998 to 2002. Ms. Young is currently the Executive Director of NashvilleHealth, an initiative focused on improving the health of the citizens of Nashville-Davidson County. NashvilleHealth addresses area health equity issues and ensures Nashville continues to be a great place to live and work. Ms. Young has been recognized by the Nashville Business Journal as a “Healthcare Hero,” and the Nashville Medical News as a “Woman to Watch.” Currently, Ms. Young is a member of the Advisory Board of the Washington, DC-based Women Business Leaders of the U.S. Healthcare Industry. Ms. Young holds a B.A. from the University of Mississippi and a M.S. from the University of Tennessee. The Board of Directors believes Ms. Young’s extensive healthcare industry experience as well as organizational leadership experience will be critical as the Company continues to address unmet medical needs.
How old is Caroline Young?
Caroline Young is 45, she's been the Independent Director of Cumberland Pharmaceuticals since 2016. There are 17 older and 2 younger executives at Cumberland Pharmaceuticals. The oldest executive at Cumberland Pharmaceuticals Inc. is Jonathan Griggs, 85, who is the Independent Director.
What's Caroline Young's mailing address?
Caroline's mailing address filed with the SEC is 1600 WEST END AVENUE, SUITE 1300, NASHVILLE, TN, 37203.
Insiders trading at Cumberland Pharmaceuticals
Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv e Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.
What does Cumberland Pharmaceuticals do?
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
What does Cumberland Pharmaceuticals's logo look like?
Complete history of Ms. Young stock trades at Cumberland Pharmaceuticals
Cumberland Pharmaceuticals executives and stock owners
Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include:
-
A. Kazimi,
Chairman of the Board, Chief Executive Officer -
A. J. Kazimi,
Founder, Chairman, Pres & CEO -
Leo Pavliv,
Executive Vice President - Operations, Chief Development Officer -
Leo B. Pavliv,
Exec. VP of Operations & Chief Devel. Officer -
Martin Cearnal,
Executive Vice President, Chief Commercial Officer, Director -
Martin E. Cearnal,
Exec. VP, Chief Commercial Officer & Director -
James Herman,
Vice President - National Accounts, Chief Compliance Officer -
James Lowrance Herman,
Sr. VP of National Accounts & Chief Compliance Officer -
Michael Bonner,
Senior Director Finance and Accounting and Chief Financial Officer -
Caroline Young,
Independent Director -
Kenneth Krogulski,
Independent Director -
James Jones,
Independent Director -
Joey Jacobs,
Independent Director -
Jonathan Griggs,
Independent Director -
Joseph Galante,
Independent Director -
Gordon Bernard,
Independent Director -
Erin Smith Gull,
Sr. Corp. Relations Associate -
Adam S. Mostafa,
Managing Director -
Cindy B. Patton,
Sr. Director of Field Marketing -
Jean W. Marstiller,
Sr. VP of Admin. Services & Corp. Sec. -
John Michael Hamm,
Director of Fin. & Accounting and CFO -
Thomas R Lawrence,
Director -
Martin S Jr Brown,
-
Chris T. Bitterman,
Vice Pres Sales & Marketing -
Rick Scott Greene,
Chief Financial Officer -
Robert Edwards,
Director -
Jean W Marstiller,
Sr. VP & Corp. Secretary -
Lawrence W Greer,
Director -
David L Lowrance,
Vice President and CFO -
Todd M. Anthony,
Vice Pres Organizational Dev -
John M. Hamm,
VP Chief Financial Officer